Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab in secondary progressive multiple sclerosis
2010-021978-11Phase 3Terminated
- Sponsor
- Biogen
- Start
- Mar 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in secondary-progressive multiple sclerosis (SPMS) comparing Natalizumab with Placebo (2 arms). Primary endpoint: Confirmed disability progression not related to relapses. Started Mar 2011; status: terminated.
02
Drugs
natalizumab
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2010-021978-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021978-11.